ClinicalTrials.gg
CompletedNCT04839393Updated Aug 21, 2023Results posted

A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy

A Phase 1 interventional study of PF-06882961 followed by PF-06882961/PF-06865571 and PF-06882961/PF-06865571 followed by PF-06882961 in Healthy Volunteer, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-21.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study will be conducted in 2 parts. Part A will investigate the potential effect of PF-06865571 on the pharmacokinetics (PK) of PF-06882961 in healthy adult participants. Part B will evaluate the effect of PF-06882961 on the PK of PF-06865571, as well as the effect of PF-06865571 on the PK of PF-06882961 in overweight adults or adults with obesity who are otherwise healthy.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female participants must be 18 to 65 years of age, inclusive, at the time of signing the ICD.

    Women can be of , however, cannot be pregnant, breastfeeding, or planning to become pregnant while participating in the study.

  2. Male and female participants who are overtly healthy (other than being overweight or obese in Part B only) as determined by medical evaluation including medical history, physical examination, and laboratory tests.
  3. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  4. and total body weight:

    Part A: BMI of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb); Part B: BMI ≥25 kg/m2 and not more than 40 kg/m2 at Screening; stable body weight, defined as \<5 kg change (per participant report) for 90 days before Screening.

  5. Capable of giving signed , which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.

Exclusion criteria

Exclusion Criteria

  1. Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  2. Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy, bariatric surgery, active inflammatory bowel disease, or an intestinal resection).
  3. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality or other conditions or situations related to COVID-19 pandemic (eg, contact with positive case, residence or travel to an area with high incidence) that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  4. Known intolerance or to GLP-1 receptor agonists.
  5. Known intolerance or hypersensitivity to DGAT2 inhibitors.
  6. Diagnosis of type 1 or type 2 diabetes mellitus or secondary forms of diabetes at screening. Note: women with prior diagnoses of gestational diabetes during pregnancy only are eligible if they meet the other eligibility criteria.
  7. History of myocardial infarction, unstable angina, arterial revascularization, stroke, Functional Class II-IV heart failure, or within 6 months of Screening.
  8. Any not considered cured (except basal cell carcinoma and squamous cell carcinoma of the skin); a study participant is considered cured if there has been no evidence of cancer recurrence in the previous 5 years (from Screening).
  9. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, or study participants with suspected medullary thyroid carcinoma per the investigator's judgment.
  10. Acute pancreatitis or history of chronic pancreatitis.
  11. Symptomatic gallbladder disease.
  12. Medical history or characteristics suggestive of genetic or syndromic obesity or obesity induced by other endocrinological disorders (eg, Cushing Syndrome).
  13. History of major depressive disorder or history of other severe psychiatric disorders (eg, schizophrenia or bipolar disorder) within the last 2 years from screening.
  14. Known medical history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic active or C, primary biliary cirrhosis, alcoholic liver disease, primary sclerosing cholangitis, hepatitis, overlap syndrome, or prior known drug-induced liver injury.
  15. History of infection.
  16. Any lifetime history of a suicide attempt.
  17. Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention.
  18. Prohibited prior/concomitant medication as per protocol.
  19. Previous administration with an drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer). An emergency use authorized or approved COVID-19 vaccine is considered a concomitant medication.
  20. Known prior participation in a clinical trial with PF-06882961 or PF-06865571.
  21. Part B only: A Patient Health Questionnaire (PHQ-9) score ≥15 obtained at Screening or Day -1.
  22. Part B only: Response of "yes" to question 4 or 5, or on any behavioral question on the C-SSRS at Screening or Day -1.
  23. A positive urine drug test.
  24. Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes of supine rest. If BP is ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility.
  25. Screening 12-lead that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results (eg, baseline >450 msec, complete LBBB, signs of an acute or indeterminate-age myocardial infarction, ST-T interval changes suggestive of myocardial ischemia, second- or third-degree AV block, or serious bradyarrhythmias or tachyarrhythmias). If the baseline uncorrected QT interval is >450 msec, this interval should be rate-corrected using the Fridericia method and the resulting QTcF should be used for decision making and reporting. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTc or QRS values should be used to determine the participant's eligibility. Computer-interpreted ECGs should be overread by a physician experienced in reading ECGs before excluding participants.
  26. A positive COVID-19 test at or after screening.
  27. Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study-specific laboratory and confirmed by a single repeat test, if deemed necessary: ≥6.5%. or ALT > . Total level > ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and are eligible for this study provided the direct bilirubin level is ≤ ULN.

    TSH > ULN or \< LLN. Serum calcitonin > ULN. Amylase or lipase > ULN. Fasting blood glucose ≥126 mg/dL. Fasting triglycerides >200 mg/dL. > ULN. \< LLN. \<80 mL/min/1.73 m2 as calculated by the CKD-EPI equation. Positive testing for HIV, HepBsAg, or HCVAb. Study participants positive for HCVAb are to be excluded unless known to have been treated with a known curative therapy and negative for . Hepatitis B vaccination is allowed.

  28. Participation in a formal weight reduction program (eg, Weight Watchers) within 90 days prior to Screening.
  29. History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening. Binge drinking is defined as a pattern of 5 (male) and 4 (female) or more alcoholic drinks in about 2 hours. As a general rule, alcohol intake should not exceed 14 units per week (1 unit = 8 ounces (240 mL) beer, 1 ounce (30 mL) of 40% spirit or 3 ounces (90 mL) of wine).
  30. Current use of tobacco or nicotine containing products in excess of the equivalent of 5 cigarettes per day.
  31. Known or suspected illicit drug use.
  32. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dose randomization (Day -1).
  33. History of sensitivity to heparin or heparin-induced thrombocytopenia if Hep-lock is used for IV blood draw.
  34. Unwilling or unable to comply with the criteria in the Lifestyle Considerations section of this protocol.
  35. Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Part A - Sequence 1

    Treatment A - PF-06882961 single dose followed by Treatment B - PF-06882961 single dose and PF-06865571 single dose

    Drug: PF-06882961 followed by PF-06882961/PF-06865571

  • Experimental
    Part A - Sequence 2

    Treatment B - PF-06882961 single dose and PF-06865571 single dose followed by Treatment A - PF-06882961 single dose

    Drug: PF-06882961/PF-06865571 followed by PF-06882961

  • Experimental
    Part B

    Period 1: PF-06865571 single dose, Period 2: PF-06882961 twice daily dose titration, Period 3: PF-06865571 single dose and PF-06882961 twice daily dosing, Period 4: PF-06865571 twice daily dosing and PF-06882961 twice daily dosing

    Drug: PF-06882961 + PF-06865571

Interventions

  • DrugPF-06882961 followed by PF-06882961/PF-06865571

    Drug pages: Danuglipron · Ervogastat

    Treatment A - PF-06882961 20 mg single dose followed by Treatment B - PF-06882961 20 mg single dose plus PF-06865571 300 mg single dose. There will be a washout interval between periods of at least 3 days.

  • DrugPF-06882961/PF-06865571 followed by PF-06882961

    Drug pages: Danuglipron · Ervogastat

    Treatment B - PF-06882961 20 mg single dose plus PF-06865571 300 mg single dose followed by Treatment A - PF-06882961 20 mg single dose. There will be a washout interval between periods of at least 3 days.

  • DrugPF-06882961 + PF-06865571

    Drug pages: Danuglipron · Ervogastat

    Period 1: PF-06865571 300 mg single dose (Day 1), Period 2: PF-06882961 10 mg twice daily dose titration up to 200 mg twice daily dosing (Days 3-46), Period 3: PF-06865571 300 mg single dose (Day 47) and PF-06882961 200 mg twice daily dosing (Days 47-48), Period 4: PF-06865571 300 mg twice daily dosing and PF-06882961 200 mg twice daily dosing (Days 49-62)

06

What researchers measure

Primary outcomes

  1. Part A: PF-06882961 Maximum Observed Concentration (Cmax)

    Cmax for PF-06882961 was observed directly from data.

    Time frame: 0 (prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16 and 24 hours post-dose on Day 1

  2. Part A: PF-06882961 Area Under the Plasma Concentration-time Profile From Time 0 to the Time 24 Hours Post-dose (AUC24)

    AUC24 for PF-06882961 was determined by Linear/Log trapezoidal method.

    Time frame: 0 (prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16 and 24 hours post-dose on Day 1

  3. Part B: PF-06865571 Cmax on Day 1 and Day 47

    Cmax for PF-06865571 was observed directly from data on Day 1 and Day 47.

    Time frame: 0 (prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 24 and 48 hours post-dose

  4. Part B: PF-06865571 Area Under the Plasma Concentration-time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) on Day 1 and Day 47

    AUClast for PF-06865571 was determined by Linear/Log trapezoidal method on Day 1 and Day 47.

    Time frame: 0 (prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 24 and 48 hours post-dose

  5. Part B: PF-06865571 Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) on Day 1 and Day 47

    AUCinf for PF-06865571 was calculated as AUClast + (Clast\*/kel) on Day 1 and Day 47. Clast\* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel was the elimination rate constant.

    Time frame: 0 (prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 24 and 48 hours post-dose

  6. Part B: PF-06882961 Cmax on Day 46 and Day 61

    Cmax for PF-06882961 was observed directly from data on Day 46 and Day 61.

    Time frame: 0 (prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose

  7. Part B: PF-06882961 Area Under the Plasma Concentration-time Profile From Time 0 to the Time 12 Hours Post-dose (AUC12) on Day 46 and Day 61

    AUC 12 for PF-06882961 was determined by Linear/Log trapezoidal method on Day 46 and Day 61.

    Time frame: 0 (prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in Part A

    An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Any AEs occurring following start of study intervention were counted as treatment emergent. Serious AEs (SAEs) were defined as any untoward medical occurrence at any dose that resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). AEs included SAEs and non-serious AEs. Relatedness to study treatment was determined by the investigator.

    Time frame: Up to 68 days

  2. Number of Participants With Clinical Laboratory Abnormalities in Part A

    Safety laboratory assessments included clinical chemistry, hematology, urinalysis, and other tests. Abnormality was determined at the investigator's discretion. Abnormalities without regard to baseline abnormalities were reported.

    Time frame: From Screening (28 days prior to the day of treatment) to Day 2 of Period 2, for a maximum of 33 Days

  3. Number of Participants With Vital Signs Data Meeting Pre-specified Criteria in Part A

    Single, supine vital signs assessments included systolic blood pressure (BP), diastolic BP and pulse rate. Abnormality in vital signs included: pulse rate \<40 beats per minute (bpm) or \>120bpm; supine diastolic BP \<50 millimeter of mercury (mmHg), increase and decrease in change from baseline (BL) of \>=20mmHg; supine systolic blood pressure \<90mmHg, increase and decrease in change from BL of \>=30mmHg.

    Time frame: From Screening (28 days prior to the day of treatment) to Day 2 of Period 2, for a maximum of 33 Days

  4. Number of Participants With Electrocardiogram (ECG) Data Meeting Pre-specified Criteria in Part A

    ECG assessments included pulse rate (PR), QT, QTcF intervals and QRS complex. ECG abnormalities criteria included: PR interval value \>= 300msec, or baseline (BL) \>200msec and \>=25% increase from BL, or BL \<=200msec and \>=50% increase from BL; QRS interval value \>= 140msec, or percent change from BL \>=50%; QTcF value \>400 and \<=480msec, or \>480 and \<=500 msec, or \>500msec, or change from BL\>30 and \<=60msec, or change from BL \>60msec.

    Time frame: From Screening (28 days prior to the day of treatment) to Day 2 of Period 2, for a maximum of 33 Days

  5. Number of Participants With TEAEs in Part B

    An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Any AEs occurring following start of study intervention were counted as treatment emergent. Serious AEs (SAEs) were defined as any untoward medical occurrence at any dose that resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). AEs included SAEs and non-serious AEs. Relatedness to study treatment was determined by the investigator.

    Time frame: Up to 173 days

  6. Number of Participants With Clinical Laboratory Abnormalities in Part B

    Safety laboratory assessments included clinical chemistry, hematology, urinalysis, and other tests. Abnormality was determined at the investigator's discretion. Abnormalities without regard to baseline abnormalities were reported.

    Time frame: From Screening (28 days prior to follow-up visit (up to 10 days after the last dose of treatment), for a maximum of 148 Days

  7. Number of Participants With Vital Signs Data Meeting Pre-specified Criteria in Part B

    Single, supine vital signs assessments included systolic blood pressure (BP), diastolic BP and pulse rate. Abnormality in vital signs included: pulse rate \<40 beats per minute (bpm) or \>120bpm; supine diastolic BP \<50 millimeter of mercury (mmHg), increase and decrease in change from BL of \>=20mmHg; supine systolic blood pressure \<90mmHg, increase and decrease in change from BL of \>=30mmHg.

    Time frame: From Screening (28 days prior to follow-up visit (up to 10 days after the last dose of treatment), for a maximum of 148 Days

  8. Change From Baseline in Body Weight for Participants in Part B

    Changes from baseline in body weight of the participants were measured.

    Time frame: At Baseline (Days -28 to 2), on Period 2, Days 6, 13, 20 ,27, 34, and 41, Period 4, Days 9 and14 and follow-up visit (Days 68-71)

  9. Number of Participants With ECG Data Meeting Pre-specified Criteria in Part B

    ECG assessments included PR, QT, QTcF intervals and QRS complex. ECG abnormalities criteria included: PR interval value \>= 300msec, or BL \>200msec and \>=25% increase from BL, or BL \<=200msec and \>=50% increase from BL; QRS interval value \>= 140msec, or percent change from BL \>=50%; QTcF value \>400 and \<=480msec, or \>480 and \<=500 msec, or \>500msec, or change from BL\>30 and \<=60msec, or change from BL \>60msec.

    Time frame: From Screening (28 days prior to follow-up visit (up to 10 days after the last dose of treatment), for a maximum of 148 Days

  10. Number of Participants With Suicidal Ideation or Behavior as Per C-SSRS Mapped to Columbia Classification Algorithm of Suicide Assessment (C-CASA) in Part B

    The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced any of the following 1: completed suicide, 2: suicide attempt (response of "yes" on "actual attempt"), 3: preparatory acts toward imminent suicidal behavior ("yes" on "aborted attempt", "interrupted attempt", "preparatory acts or behavior"), 4: any suicidal behavior or ideation, suicidal ideation ("yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent"), 7: self-injurious behavior, no suicidal intent ("yes" on "has participant engaged in non-suicidal self-injurious behavior").

    Time frame: At Screening (Days -28 to -2), Baseline (Period 1 Day -1), on Period 2, Days 6, 13, 20, 27, 34 and 41, Period 4, Days 2, 9 and 14 and follow-up visit (Days 68-71)

  11. Number of Participants With Response to PHQ-9 in Part B

    The PHQ-9 is a 9 item self-report scale for the assessment of depressive symptoms. The questions included "little interest/pleasure in things", "feeling down depressed or hopeless", "trouble falling or staying asleep", "feeling tired or little energy", "poor appetite or overeating", "feeling bad about yourself", "trouble concentrating on things", "moving slowly or fidgety/restless" and "thoughts you be better off dead". Each item was scored on scale of "not at all", "several days", "more than half the days" to "nearly every day". Total score range: 0-27 (each item with scale from 0 \[not at all\] to 3 \[nearly every day\]. Higher score=greater severity). Any participant with a response of any scale other than "not at all" to any of the 9 questions was counted.

    Time frame: At Screening (Days -28 to -2), Baseline (Period 1 Day -1), on Period 2, Days 6, 13, 20, 27, 34 and 41, Period 4, Days 2, 9 and 14 and follow-up visit (Days 68-71)

07

Results

Posted Aug 21, 2023

Participant flow

A total of 8 participants were enrolled in Part A of the study and 19 participants were enrolled in Part B of the study.

Participant flow — Overall Study
MilestonePart A Sequence 1Part A Sequence 2Part B
Started4419
Received treatment4419
Completed4416
Not completed003
Withdrew: Adverse event002
Withdrew: Withdrawal by participant001

Outcome measures

PrimaryPart A: PF-06882961 Maximum Observed Concentration (Cmax)

Cmax for PF-06882961 was observed directly from data.

Time frame:
0 (prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16 and 24 hours post-dose on Day 1
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Part A: PF-06882961 Maximum Observed Concentration (Cmax)
nanogram per milliliter (ng/mL)PF-06882961 20 mgPF-06882961 20 mg + PF-06865571 300 mg
Part A: PF-06882961 Maximum Observed Concentration (Cmax)15.69 ± 19817.09 ± 265
Statistical analysis
  • PF-06882961 20 mg vs PF-06882961 20 mg + PF-06865571 300 mg · Mixed Models Analysis · Adjusted geometric mean ratio (%): 108.86 · 90% CI 87.24 to 135.84
PrimaryPart A: PF-06882961 Area Under the Plasma Concentration-time Profile From Time 0 to the Time 24 Hours Post-dose (AUC24)

AUC24 for PF-06882961 was determined by Linear/Log trapezoidal method.

Time frame:
0 (prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16 and 24 hours post-dose on Day 1
Reported as:
Geometric mean · nanogram*hour per milliliter (ng.hr/mL)
Part A: PF-06882961 Area Under the Plasma Concentration-time Profile From Time 0 to the Time 24 Hours Post-dose (AUC24)
nanogram*hour per milliliter (ng.hr/mL)PF-06882961 20 mgPF-06892961 20 mg + PF-06865571 300 mg
Part A: PF-06882961 Area Under the Plasma Concentration-time Profile From Time 0 to the Time 24 Hours Post-dose (AUC24)109.5 ± 198123.9 ± 311
Statistical analysis
  • PF-06882961 20 mg vs PF-06892961 20 mg + PF-06865571 300 mg · Mixed Models Analysis · Adjusted geometric mean ratio: 113.14 · 90% CI 89.34 to 143.28
PrimaryPart B: PF-06865571 Cmax on Day 1 and Day 47

Cmax for PF-06865571 was observed directly from data on Day 1 and Day 47.

Time frame:
0 (prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 24 and 48 hours post-dose
Reported as:
Geometric mean · ng/mL
Part B: PF-06865571 Cmax on Day 1 and Day 47
ng/mLDay 1 (PF-06865571 300 mg)Day 47 (PF-06865571 300 mg + PF-06882961 200 mg BID)
Part B: PF-06865571 Cmax on Day 1 and Day 472078 ± 37791 ± 41
Statistical analysis
  • Day 1 (PF-06865571 300 mg) vs Day 47 (PF-06865571 300 mg + PF-06882961 200 mg BID) · Mixed Models Analysis · Adjusted geometric mean ratio: 38.73 · 90% CI 32.80 to 45.74
PrimaryPart B: PF-06865571 Area Under the Plasma Concentration-time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) on Day 1 and Day 47

AUClast for PF-06865571 was determined by Linear/Log trapezoidal method on Day 1 and Day 47.

Time frame:
0 (prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 24 and 48 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Part B: PF-06865571 Area Under the Plasma Concentration-time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) on Day 1 and Day 47
ng*hr/mLDay 1 (PF-06865571 300 mg)Day 47 (PF-06865571 300 mg + PF-06882961 200 mg BID)
Part B: PF-06865571 Area Under the Plasma Concentration-time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) on Day 1 and Day 479011 ± 386630 ± 40
Statistical analysis
  • Day 1 (PF-06865571 300 mg) vs Day 47 (PF-06865571 300 mg + PF-06882961 200 mg BID) · Mixed Models Analysis · Adjusted geometric mean ratio: 73.91 · 90% CI 67.95 to 80.40
PrimaryPart B: PF-06865571 Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) on Day 1 and Day 47

AUCinf for PF-06865571 was calculated as AUClast + (Clast\*/kel) on Day 1 and Day 47. Clast\* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel was the elimination rate constant.

Time frame:
0 (prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 24 and 48 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Part B: PF-06865571 Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) on Day 1 and Day 47
ng*hr/mLDay 1 (PF-06865571 300 mg)Day 47 (PF-06865571 300 mg + PF-06882961 200 mg BID)
Part B: PF-06865571 Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) on Day 1 and Day 479029 ± 386726 ± 43
Statistical analysis
  • Day 1 (PF-06865571 300 mg) vs Day 47 (PF-06865571 300 mg + PF-06882961 200 mg BID) · Mixed Models Analysis · Adjusted geometric mean ratio: 73.20 · 90% CI 66.82 to 80.18
PrimaryPart B: PF-06882961 Cmax on Day 46 and Day 61

Cmax for PF-06882961 was observed directly from data on Day 46 and Day 61.

Time frame:
0 (prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose
Reported as:
Geometric mean · ng/mL
Part B: PF-06882961 Cmax on Day 46 and Day 61
ng/mLDay 46 (PF-06882961 Titration up to 200 mg BID)Day 61 (PF-06865571 300 mg BID + PF-06882961 200 mg BID)
Part B: PF-06882961 Cmax on Day 46 and Day 611187 ± 1151393 ± 107
Statistical analysis
  • Day 46 (PF-06882961 Titration up to 200 mg BID) vs Day 61 (PF-06865571 300 mg BID + PF-06882961 200 mg BID) · Mixed Models Analysis · Adjusted geometric mean ratio: 115.30 · 90% CI 85.37 to 155.73
PrimaryPart B: PF-06882961 Area Under the Plasma Concentration-time Profile From Time 0 to the Time 12 Hours Post-dose (AUC12) on Day 46 and Day 61

AUC 12 for PF-06882961 was determined by Linear/Log trapezoidal method on Day 46 and Day 61.

Time frame:
0 (prior to dosing), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose
Reported as:
Geometric mean · ng.hr/mL
Part B: PF-06882961 Area Under the Plasma Concentration-time Profile From Time 0 to the Time 12 Hours Post-dose (AUC12) on Day 46 and Day 61
ng.hr/mLDay 46 (PF-06882961 Titration up to 200 mg BID)Day 61 (PF-06865571 300 mg BID + PF-06882961 200 mg BID)
Part B: PF-06882961 Area Under the Plasma Concentration-time Profile From Time 0 to the Time 12 Hours Post-dose (AUC12) on Day 46 and Day 617682 ± 999312 ± 99
Statistical analysis
  • Day 46 (PF-06882961 Titration up to 200 mg BID) vs Day 61 (PF-06865571 300 mg BID + PF-06882961 200 mg BID) · Mixed Models Analysis · Adjusted geometric mean ratio: 118.64 · 90% CI 94.05 to 149.66
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) in Part A

An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Any AEs occurring following start of study intervention were counted as treatment emergent. Serious AEs (SAEs) were defined as any untoward medical occurrence at any dose that resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). AEs included SAEs and non-serious AEs. Relatedness to study treatment was determined by the investigator.

Time frame:
Up to 68 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in Part A
ParticipantsPF-06882961 20 mgPF-06882961 20 mg + PF-06865571 300 mg
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in Part A00
SecondaryNumber of Participants With Clinical Laboratory Abnormalities in Part A

Safety laboratory assessments included clinical chemistry, hematology, urinalysis, and other tests. Abnormality was determined at the investigator's discretion. Abnormalities without regard to baseline abnormalities were reported.

Time frame:
From Screening (28 days prior to the day of treatment) to Day 2 of Period 2, for a maximum of 33 Days
Reported as:
Count of participants · Participants
Number of Participants With Clinical Laboratory Abnormalities in Part A
ParticipantsPF-06882961 20 mgPF-06882961 20 mg + PF-06865571 300 mg
Number of Participants With Clinical Laboratory Abnormalities in Part A23
SecondaryNumber of Participants With Vital Signs Data Meeting Pre-specified Criteria in Part A

Single, supine vital signs assessments included systolic blood pressure (BP), diastolic BP and pulse rate. Abnormality in vital signs included: pulse rate \<40 beats per minute (bpm) or \>120bpm; supine diastolic BP \<50 millimeter of mercury (mmHg), increase and decrease in change from baseline (BL) of \>=20mmHg; supine systolic blood pressure \<90mmHg, increase and decrease in change from BL of \>=30mmHg.

Time frame:
From Screening (28 days prior to the day of treatment) to Day 2 of Period 2, for a maximum of 33 Days
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs Data Meeting Pre-specified Criteria in Part A
ParticipantsPF-06882961 20 mgPF-06882961 20 mg + PF-06865571 300 mg
Supine systolic BP value <90mmHg00
Supine systolic BP change >=30mmHg increase00
Supine systolic BP change >=30mmHg decrease01
Supine diastolic BP value <50mmHg00
Supine diastolic BP change >=20mmHg increase00
Supine diastolic BP change >=20mmHg decrease00
Pulse rate value <40bpm00
Pulse rate value >120bpm00
SecondaryNumber of Participants With Electrocardiogram (ECG) Data Meeting Pre-specified Criteria in Part A

ECG assessments included pulse rate (PR), QT, QTcF intervals and QRS complex. ECG abnormalities criteria included: PR interval value \>= 300msec, or baseline (BL) \>200msec and \>=25% increase from BL, or BL \<=200msec and \>=50% increase from BL; QRS interval value \>= 140msec, or percent change from BL \>=50%; QTcF value \>400 and \<=480msec, or \>480 and \<=500 msec, or \>500msec, or change from BL\>30 and \<=60msec, or change from BL \>60msec.

Time frame:
From Screening (28 days prior to the day of treatment) to Day 2 of Period 2, for a maximum of 33 Days
Reported as:
Count of participants · Participants
Number of Participants With Electrocardiogram (ECG) Data Meeting Pre-specified Criteria in Part A
ParticipantsPF-06882961 20 mgPF-06882961 20 mg + PF-06865571 300 mg
PR interval value >= 300 msec00
PR interval %change >=25/50% (BL >200 msec and >=25% increase or BL <=200 msec and >=50% increase)00
QRS interval value>=140 msec00
QRS interval %change >=50%00
QTcF value >450 and <=480 msec00
QTcF value >480 and <=500 msec00
QTcF value >500 msec00
QTcF change >30 and <=60 msec00
QTcF change >60 msec00
SecondaryNumber of Participants With TEAEs in Part B

An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Any AEs occurring following start of study intervention were counted as treatment emergent. Serious AEs (SAEs) were defined as any untoward medical occurrence at any dose that resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). AEs included SAEs and non-serious AEs. Relatedness to study treatment was determined by the investigator.

Time frame:
Up to 173 days
Reported as:
Count of participants · Participants
Number of Participants With TEAEs in Part B
ParticipantsPF-06865571 300 mgPF-06882961 Titration up to 200 mg BIDPF-06865571 300 mg + PF-06882961 200 mg BIDPF-06865571 300 mg BID + PF-06882961 200 mg BID
All-causality TEAEs118610
Treatment-related TEAEs116610
SecondaryNumber of Participants With Clinical Laboratory Abnormalities in Part B

Safety laboratory assessments included clinical chemistry, hematology, urinalysis, and other tests. Abnormality was determined at the investigator's discretion. Abnormalities without regard to baseline abnormalities were reported.

Time frame:
From Screening (28 days prior to follow-up visit (up to 10 days after the last dose of treatment), for a maximum of 148 Days
Reported as:
Count of participants · Participants
Number of Participants With Clinical Laboratory Abnormalities in Part B
ParticipantsPF-06865571 300 mgPF-06882961 Titration up to 200 mg BIDPF-06865571 300 mg + PF-06882961 200 mg BIDPF-06865571 300 mg BID + PF-06882961 200 mg BID
Number of Participants With Clinical Laboratory Abnormalities in Part B016015
SecondaryNumber of Participants With Vital Signs Data Meeting Pre-specified Criteria in Part B

Single, supine vital signs assessments included systolic blood pressure (BP), diastolic BP and pulse rate. Abnormality in vital signs included: pulse rate \<40 beats per minute (bpm) or \>120bpm; supine diastolic BP \<50 millimeter of mercury (mmHg), increase and decrease in change from BL of \>=20mmHg; supine systolic blood pressure \<90mmHg, increase and decrease in change from BL of \>=30mmHg.

Time frame:
From Screening (28 days prior to follow-up visit (up to 10 days after the last dose of treatment), for a maximum of 148 Days
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs Data Meeting Pre-specified Criteria in Part B
ParticipantsPF-06865571 300 mgPF-06882961 Titration up to 200 mg BIDPF-06865571 300 mg + PF-06882961 200 mg BIDPF-06865571 300 mg BID + PF-06882961 200 mg BID
Supine systolic BP value <90mmHg0000
Supine systolic BP change >=30mmHg increase0000
Supine systolic BP change >=30mmHg decrease0000
Supine diastolic BP value <50mmHg0000
Supine diastolic BP change >=20mmHg increase0101
Supine diastolic BP change >=20mmHg decrease0000
Pulse rate value <40bpm0000
Pulse rate value >120bpm0000
SecondaryChange From Baseline in Body Weight for Participants in Part B

Changes from baseline in body weight of the participants were measured.

Time frame:
At Baseline (Days -28 to 2), on Period 2, Days 6, 13, 20 ,27, 34, and 41, Period 4, Days 9 and14 and follow-up visit (Days 68-71)
Reported as:
Mean · kilogram (kg)
Change From Baseline in Body Weight for Participants in Part B
kilogram (kg)All Participants
Period 2 Day 6-0.73 ± 1.999
Period 2 Day 13-1.49 ± 2.260
Period 2 Day 20-2.48 ± 2.242
Period 2 Day 27-3.32 ± 2.525
Period 2 Day 34-4.76 ± 3.141
Period 2 Day 41-5.39 ± 2.599
Period 4 Day 2-6.09 ± 3.088
Period 4 Day 9-6.89 ± 3.299
Period 4 Day 14-6.93 ± 3.632
Follow-up-4.59 ± 3.916
SecondaryNumber of Participants With ECG Data Meeting Pre-specified Criteria in Part B

ECG assessments included PR, QT, QTcF intervals and QRS complex. ECG abnormalities criteria included: PR interval value \>= 300msec, or BL \>200msec and \>=25% increase from BL, or BL \<=200msec and \>=50% increase from BL; QRS interval value \>= 140msec, or percent change from BL \>=50%; QTcF value \>400 and \<=480msec, or \>480 and \<=500 msec, or \>500msec, or change from BL\>30 and \<=60msec, or change from BL \>60msec.

Time frame:
From Screening (28 days prior to follow-up visit (up to 10 days after the last dose of treatment), for a maximum of 148 Days
Reported as:
Count of participants · Participants
Number of Participants With ECG Data Meeting Pre-specified Criteria in Part B
ParticipantsPF-06882961 Titration up to 200 mg BIDPF-06865571 300 mg BID + PF-06882961 200 mg BID
PR interval value>=300 msec01
PR interval %change >=25/50% (BL >200 msec and >=25% increase or BL <=200 msec and >=50% increase)00
QRS interval value>=140 msec00
QRS interval %change >=50%00
QTcF value >450 and <=480 msec00
QTcF value >480 and <=500 msec00
QTcF value >500 msec00
QTcF change >30 and <=60 msec00
QTcF change >60 msec00
SecondaryNumber of Participants With Suicidal Ideation or Behavior as Per C-SSRS Mapped to Columbia Classification Algorithm of Suicide Assessment (C-CASA) in Part B

The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced any of the following 1: completed suicide, 2: suicide attempt (response of "yes" on "actual attempt"), 3: preparatory acts toward imminent suicidal behavior ("yes" on "aborted attempt", "interrupted attempt", "preparatory acts or behavior"), 4: any suicidal behavior or ideation, suicidal ideation ("yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent"), 7: self-injurious behavior, no suicidal intent ("yes" on "has participant engaged in non-suicidal self-injurious behavior").

Time frame:
At Screening (Days -28 to -2), Baseline (Period 1 Day -1), on Period 2, Days 6, 13, 20, 27, 34 and 41, Period 4, Days 2, 9 and 14 and follow-up visit (Days 68-71)
Reported as:
Count of participants · Participants
Number of Participants With Suicidal Ideation or Behavior as Per C-SSRS Mapped to Columbia Classification Algorithm of Suicide Assessment (C-CASA) in Part B
ParticipantsAll Participants
Baseline0
Period 2 Day 60
Period 2 Day 130
Period 2 Day 200
Period 2 Day 270
Period 2 Day 340
Period 2 Day 410
Period 4 Day 20
Period 4 Day 90
Period 4 Day 140
Follow-up0
SecondaryNumber of Participants With Response to PHQ-9 in Part B

The PHQ-9 is a 9 item self-report scale for the assessment of depressive symptoms. The questions included "little interest/pleasure in things", "feeling down depressed or hopeless", "trouble falling or staying asleep", "feeling tired or little energy", "poor appetite or overeating", "feeling bad about yourself", "trouble concentrating on things", "moving slowly or fidgety/restless" and "thoughts you be better off dead". Each item was scored on scale of "not at all", "several days", "more than half the days" to "nearly every day". Total score range: 0-27 (each item with scale from 0 \[not at all\] to 3 \[nearly every day\]. Higher score=greater severity). Any participant with a response of any scale other than "not at all" to any of the 9 questions was counted.

Time frame:
At Screening (Days -28 to -2), Baseline (Period 1 Day -1), on Period 2, Days 6, 13, 20, 27, 34 and 41, Period 4, Days 2, 9 and 14 and follow-up visit (Days 68-71)
Reported as:
Count of participants · Participants
Number of Participants With Response to PHQ-9 in Part B
ParticipantsAll Participants
Baseline2
Period 2 Day 60
Period 2 Day 130
Period 2 Day 200
Period 2 Day 270
Period 2 Day 340
Period 2 Day 410
Period 4 Day 20
Period 4 Day 90
Period 4 Day 140
Follow-up0

Adverse events

Collected over Up to 68 days for Part A and up to 173 days for Part B.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-06882961 20 mg0/8 (0%)0/8 (0%)0/8 (0%)
PF-06882961 20 mg + PF-06865571 300 mg0/8 (0%)0/8 (0%)0/8 (0%)
PF-06865571 300 mg0/19 (0%)0/19 (0%)1/19 (5.3%)
PF-06882961 Titration up to 200 mg BID0/19 (0%)0/19 (0%)18/19 (94.7%)
PF-06865571 300 mg + PF-06882961 200 mg BID0/16 (0%)0/16 (0%)6/16 (37.5%)
PF-06865571 300 mg BID + PF-06882961 200 mg BID0/16 (0%)0/16 (0%)10/16 (62.5%)
Most frequent other events
Showing 10 of 21
Most frequent other events
EventPF-06882961 20 mgPF-06882961 20 mg + PF-06865571 300 mgPF-06865571 300 mgPF-06882961 Titration up to 200 mg BIDPF-06865571 300 mg + PF-06882961 200 mg BIDPF-06865571 300 mg BID + PF-06882961 200 mg BID
NauseaGastrointestinal disorders0/80/81/1912/191/166/16
Decreased appetiteMetabolism and nutrition disorders0/80/80/1910/190/160/16
DyspepsiaGastrointestinal disorders0/80/80/198/190/162/16
SomnolenceNervous system disorders0/80/80/198/190/161/16
VomitingGastrointestinal disorders0/80/80/197/193/166/16
ConstipationGastrointestinal disorders0/80/80/196/191/160/16
HeadacheNervous system disorders0/80/80/194/191/164/16
Abdominal discomfortGastrointestinal disorders0/80/80/193/191/162/16
Abdominal distensionGastrointestinal disorders0/80/80/193/190/160/16
DiarrhoeaGastrointestinal disorders0/80/80/193/190/161/16

Baseline characteristics

Age, Customized
Age, Customized(Participants)Part A Sequence 1Part A Sequence 2Part BTotal
18-44 Years33713
45-64 Years111214
>=65 Years0000
Sex: Female, Male
Sex: Female, Male(Participants)Part A Sequence 1Part A Sequence 2Part BTotal
Female1113
Male331824
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A Sequence 1Part A Sequence 2Part BTotal
White211518
Black or African American2349
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A Sequence 1Part A Sequence 2Part BTotal
Hispanic or Latino1157
Not Hispanic or Latino331420
08

Study locations

1 site
  • Orange County Research Center
    Tustin, California 92780, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Oct 2021, 6 months.

Results were first posted in Aug 2023, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2021
First posted
Apr 9, 2021
StartActual
Apr 5, 2021
Primary completionActual
Oct 10, 2021
CompletionActual
Nov 8, 2021
Results first posted
Aug 21, 2023
Last update
Aug 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04839393
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 9, 2021
Start date
Apr 5, 2021
Primary completion
Oct 10, 2021
Completion
Nov 8, 2021
Results posted
Aug 21, 2023
Last update
Aug 21, 2023

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Danuglipron · Ervogastat

Start the discussion